Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple solid tumors
Single Center Observational Study Using Spinal Laser Interstitial Thermal Therapy (sLITT) in the Treatment of Spine Metastases and Tumors
This observational study aims to assess the efficacy and safety of spinal laser interstitial thermal therapy for definitive treatment of metastases and tumors, comparing its tumor control rates with conventional open…
NCT06548061 - New trial
Other blood cancers and transplant
Phase II Study of IM-TMI in High-Risk Hematologic Malignancies
This trial by UIC is evaluating the addition of intensity-modulated total marrow irradiation (9Gy) to standard FluBu4 conditioning and post-transplant cyclophosphamide for high-risk AML, CML, and MDS patients…
NCT06802315 - New trial
Other blood cancers and transplant
Phase I Study of Ruxolitinib Plus Abemaciclib for Patients With Primary or Post-PV/ET Myelofibrosis
Memorial Sloan Kettering is assessing the safety and efficacy of combining ruxolitinib (a JAK1 inhibitor) with abemaciclib (a CDK4/6 inhibitor) in patients with primary or post-polycythemia vera/essential…
NCT05714072 - Trial result
Multiple solid tumors
Nonoperative Management of Early-Stage dMMR Tumors Offers Organ Preservation
A phase 2 trial with 117 patients having stage I–III mismatch repair-deficient (dMMR) solid tumors, including locally advanced rectal and other nonrectal cancers, evaluated neoadjuvant PD-1 blockade with dostarlimab.…
- Trial result
Multiple solid tumors
Next-Generation KRAS G12C Inhibitor D3S-001 Demonstrates Robust Activity in Advanced Solid Tumors
In this phase 1 trial, D3S-001 was evaluated in KRAS G12C-mutant advanced tumors (42 patients in the dose-escalation phase and 20 NSCLC patients pretreated with prior G12C inhibitors) and exhibited dose-dependent…
- Trial result
Non-small cell lung cancer
Zongertinib Delivers Robust Efficacy in Previously Treated HER2-Mutant NSCLC
In a phase 1a-1b multicohort trial, zongertinib, an oral, irreversible, HER2-selective tyrosine kinase inhibitor (TKI), demonstrated impressive activity in patients with previously treated HER2-mutant NSCLC. In…
- Trial result
Cervical and other gynecologic cancers
Induction Chemotherapy Enhances Survival in Locally Advanced Cervical Cancer
In the INTERLACE phase 3 trial involving 500 patients, adding a short-course induction regimen of carboplatin and paclitaxel to standard cisplatin-based chemoradiotherapy significantly improved 5-year…
- Trial result
Breast cancer
Trastuzumab Deruxtecan Enhances Quality of Life in HER2-Low Metastatic Breast Cancer
In the DESTINY-Breast04 trial, patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan maintained stable global health status and quality of life over a longer treatment duration, with…
- Trial result
Breast cancer
Breast Tumor-Bed Biopsy Falls Short of Sufficient pCR Prediction in Neoadjuvant Breast Cancer
In the phase 2 NRG-BR005 trial of 101 evaluable patients with operable invasive ductal carcinoma who achieved a clinical and radiological complete or near-complete response post-neoadjuvant chemotherapy, adding…
- Trial result
Breast cancer
Chemotherapy-Free Triplet Regimen Shows Promise in Pre-Treated HR+/HER2+ Metastatic Breast Cancer
In this phase 2a study of 51 heavily pretreated patients with hormone receptor-positive, HER2-positive metastatic breast cancer, the chemotherapy-free combination of zanidatamab, palbociclib, and fulvestrant achieved…
- Trial result
Prostate cancer
Elective Nodal Radiotherapy Outperforms MDT in Oligorecurrent Nodal Prostate Cancer
In the phase 2 PEACE V-STORM trial of 190 evaluable patients with PET-detected pelvic nodal recurrences, elective nodal radiotherapy (ENRT) with androgen deprivation achieved a 4-year metastasis-free survival of 76%…
- Trial result
Prostate cancer
Enzalutamide Plus ADT Shows Prognostic Benefit Tied to PSA Response in mHSPC
In this secondary analysis of the ARCHES phase 3 trial with 1,150 men, enzalutamide added to androgen deprivation therapy (ADT) improved radiographic progression-free and overall survival across PSA subgroups.…
- Trial result
Lymphoma
Effective Chemo-Free Therapy: Brentuximab Vedotin Plus Nivolumab Yields Durable Response in Older Hodgkin Lymphoma
In this phase II study targeting patients over 60 or those unfit for standard chemotherapy, the combination of brentuximab vedotin (BV) and nivolumab demonstrated promising long-term outcomes. With a median follow-up…
- Trial result
Multiple myeloma
ISB 2001, a Novel Trispecific Antibody, Shows Robust Activity in Relapsed/Refractory Multiple Myeloma
In this first-in-human phase 1 study, 21 heavily pre-treated relapsed/refractory multiple myeloma (RRMM) patients across 7 dose levels (5–1200 μg/kg) received weekly subcutaneous injections of ISB 2001 with step-up…
- Trial result
Uterine (endometrial) cancer
Lynch-like MSI-H Endometrial Cancer Exhibits Superior Outcomes with Pembrolizumab
In this phase 2 trial of recurrent platinum-resistant MSI-H/dMMR endometrial cancer patients fully sequenced via whole exome and FoundationOne, the Lynch-like subgroup achieved a 100% objective response rate compared…
- Trial result
Stomach and esophageal cancer
Dual HER2-Targeting Zanidatamab Shows Promise in Pre-Treated Gastroesophageal Adenocarcinoma
In this phase 1 trial of 70 heavily pretreated patients with HER2-expressing gastroesophageal adenocarcinoma, zanidatamab monotherapy yielded a confirmed objective response rate of 32.1%, while combining it with…
- Trial result
Colorectal cancer
Cetuximab β Plus FOLFIRI Delivers Superior Outcomes in Chinese mCRC Patients
In this phase 3 trial of 505 RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients, adding cetuximab β to FOLFIRI as a first-line treatment significantly improved median progression-free survival (13.1 vs.…
- Trial result
Bladder and urothelial cancer
Atezolizumab Combined with Personalized Neoantigen Vaccine Shows Feasibility in Urothelial Cancer
In this phase 1 trial, 10 out of 12 enrolled urothelial cancer patients successfully received the personalized neoantigen vaccine PGV001 alongside atezolizumab, with a median vaccine production time of 20.3 weeks.…
- Trial result
Liver and bile duct cancer
Nivolumab Plus Ipilimumab as First-Line Therapy Improves Survival in Unresectable Hepatocellular Carcinoma
In the CheckMate 9DW phase 3 trial involving 668 patients with unresectable HCC, nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg), followed by nivolumab maintenance, significantly improved overall survival (median OS…
- Trial result
Other blood cancers and transplant
High-Dose Palifermin Shows Promise in Preventing Acute GVHD Following Unrelated Donor HCT
In this phase 1/2 trial of 31 patients undergoing reduced-intensity conditioning with HLA-matched unrelated donor peripheral-blood hematopoietic cell transplantation (HCT), palifermin was administered in escalating…
- New trial
Non-small cell lung cancer
Phase 2 Trial: Subcutaneous Nivolumab with Ipilimumab and Chemotherapy in Untreated NSCLC
Bristol-Myers Squibb is evaluating two dosing regimens of subcutaneous nivolumab combined with intravenous ipilimumab and standard chemotherapy in patients with previously untreated metastatic or recurrent NSCLC to…
NCT06946797 - New trial
Non-small cell lung cancer
Phase II Study: Neoadjuvant Dual Checkpoint Blockade in Resectable NSCLC
Mayo Clinic is evaluating a fixed-dose combination of cemiplimab and fianlimab given neoadjuvantly in patients with stage IB–IIIB NSCLC, aiming to enhance preoperative tumor cell eradication and potentially improve…
NCT06918132 - New trial
Non-small cell lung cancer
Phase 1 Study: Dose Escalation of DZD6008 in EGFR-Mutant Advanced NSCLC
Dizal Pharmaceuticals is assessing DZD6008, an EGFR (brain-blood barrier positive) inhibitor, across multiple dose escalation cohorts to evaluate its safety, tolerability, pharmacokinetics, and antitumor efficacy in…
NCT06905197 - New trial
Non-small cell lung cancer
Phase 2 Study: ctDNA-Guided Neoadjuvant and Adjuvant Pembrolizumab in Early-Stage NSCLC
University of Miami is evaluating whether circulating tumor DNA (ctDNA) can predict response to neoadjuvant platinum-based chemotherapy and surgery, and guide adjuvant pembrolizumab treatment to prevent cancer…
NCT06902272 - New trial
Brain and CNS tumors
Phase I Study: Safety and Feasibility of IL-8 Receptor Modified CD70 CAR T Therapy in pHGG
University of Florida is assessing the safety and feasibility of autologous, IL-8 receptor (CXCR2) modified CD70 CAR T cells in pediatric high-grade gliomas, with dose escalation across three cohorts (1x10^6, 1x10^7,…
NCT06946680 - New trial
Brain and CNS tumors
Phase Ib Study: Evaluating CUE-102 in Recurrent Glioblastoma
Dana-Farber is assessing the safety and recommended dosing of CUE-102—a WT-1-pHLA-IL2-Fc fusion protein—in HLA-A*0201-positive glioblastoma patients at first recurrence, with daily dosing in 21-day cycles and imaging…
NCT06917885 - New trial
Brain and CNS tumors
Phase Ib Trial: ABBV-637/ABBV-155 with ERAS-801 in EGFR-Amplified GBM
Memorial Sloan Kettering Cancer Center is assessing the safety of ABBV-637 or ABBV-155, given alone or with ERAS-801, in recurrent and newly diagnosed EGFR-amplified, IDH-wt glioblastoma, with treatment tailored…
NCT06934889 - New trial
Brain and CNS tumors
MATCHPOINT - Combined Immunotherapy for Relapsed/Progressive Medulloblastoma
University of Florida is piloting a novel immunotherapy approach for children and young adults with relapsed/progressive medulloblastoma (Group 3/4) by combining adoptive cellular therapy (ex vivo expanded…
NCT06514898 - New trial
Breast cancer
Phase I Trial: HER2-Directed Peptide Vaccine in Locally Advanced Breast Cancer
This study tests an investigational HER2-directed peptide vaccine designed to activate the immune system against high-risk, HER2-positive breast cancer through a series of intramuscular injections given every 21 days…
NCT06949410 - New trial
Breast cancer
Phase 2 Trial: Ultra-Hypofractionated Whole Breast Irradiation With Concomitant Lumpectomy Cavity Boost
City of Hope Medical Center is evaluating a five-fraction regimen that delivers both whole breast and lumpectomy cavity radiation over consecutive business days, aiming to reduce treatment time while maintaining…
NCT06954831
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.